Stock Analysis

Scienture Holdings Second Quarter 2025 Earnings: US$0.47 loss per share (vs US$1.16 loss in 2Q 2024)

NasdaqCM:SCNX 1 Year Share Price vs Fair Value
NasdaqCM:SCNX 1 Year Share Price vs Fair Value
Explore Scienture Holdings's Fair Values from the Community and select yours
Advertisement

Scienture Holdings (NASDAQ:SCNX) Second Quarter 2025 Results

Key Financial Results

  • Net loss: US$6.72m (loss widened by 314% from 2Q 2024).
  • US$0.47 loss per share.
earnings-and-revenue-history
NasdaqCM:SCNX Earnings and Revenue History August 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Scienture Holdings shares are down 7.1% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 4 warning signs for Scienture Holdings (2 are a bit unpleasant) you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqCM:SCNX

Scienture Holdings

Operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.

Moderate risk with mediocre balance sheet.

Advertisement